Smoker

JTI RESEARCH: £9.3 BILLION LOST TO ILLEGAL TOBACCO, BUT LOCAL COUNCILS REFUSE TO ACT

Retrieved on: 
Tuesday, November 21, 2023
Sale, Smoker, Isle, City, Hull, HMRC, JTI, Police Federation of Australia, Communication, Blight, Freedom of information, Crime, Pharmaceutical industry, Tobacco

Over this five-year period, Rochdale, Havering, and Kingston upon Thames were amongst the councils refusing to act.

Key Points: 
  • Over this five-year period, Rochdale, Havering, and Kingston upon Thames were amongst the councils refusing to act.
  • Some councils, such as Hull, carried out over 249 investigations in the same time period, resulting in 53 criminal prosecutions.
  • HMRC estimate that since 2018, £9.3 billion in tax revenue1 has been lost due to illegal tobacco to cigarettes and hand-rolling tobacco.
  • Freedom of Information requests sent to 96 councils across England and Wales, show significant variation between the approaches taken by local councils.

IMPERIAL TOBACCO CANADA STANDS BY ZONNIC AS A TOBACCO HARM REDUCTION TOOL

Retrieved on: 
Wednesday, November 15, 2023
Sale, Health Canada, Smoker, Heated tobacco product, Foreign policy, Imperial Tobacco Canada, Nicotine, Advertising, NRT, Smoking, Pharmacy, Tobacco

MONTREAL, Nov. 15, 2023 /CNW/ - Despite the criticism from health groups, Imperial Tobacco Canada (ITCAN) believes that ZONNIC, a Nicotine Replacement Therapy (NRT) product authorized for sale by Health Canada, will help adult Canadians smokers quit.

Key Points: 
  • MONTREAL, Nov. 15, 2023 /CNW/ - Despite the criticism from health groups, Imperial Tobacco Canada (ITCAN) believes that ZONNIC, a Nicotine Replacement Therapy (NRT) product authorized for sale by Health Canada, will help adult Canadians smokers quit.
  • "I want to be absolutely clear, ZONNIC is not a tobacco product.
  • "It is licensed, regulated and advertised in the same way as any other smoking cessation product on the market.
  • ZONNIC is not promoted any differently than any other competing smoking cessation product in Canada.

RLX Technology Announces Unaudited Third Quarter 2023 Financial Results

Retrieved on: 
Monday, November 13, 2023
Ratio, Smoker, Research, NYSE, RLX Technologies, Tobacco, ADS, RLX, GAAP, Video game, Beauty salon, Bank, Pharmaceutical industry, Cryptocurrency

BEIJING, Nov. 13, 2023 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE: RLX), a leading branded e-vapor company in China, today announced its unaudited financial results for the third quarter ended September 30, 2023.

Key Points: 
  • BEIJING, Nov. 13, 2023 /PRNewswire/ -- RLX Technology Inc. ("RLX Technology" or the "Company") (NYSE: RLX), a leading branded e-vapor company in China, today announced its unaudited financial results for the third quarter ended September 30, 2023.
  • Net revenues were RMB428.1 million (US$58.7 million) in the third quarter of 2023, compared with RMB1,044.4 million in the same period of 2022.
  • For more information on the Company's non-GAAP financial measures, please see the section "Non-GAAP Financial Measures" and the table captioned "Unaudited Reconciliation of GAAP and Non-GAAP Results" set forth at the end of this press release.
  • Mr. Chao Lu, Chief Financial Officer of RLX Technology, commented, "In the third quarter of 2023, we continued to face significant headwinds due to competition from illegal products.

The FEELM 2.0 Ushers in the New Generation of Disposable 2.0

Retrieved on: 
Friday, November 10, 2023
Pressure, Customer, Smoker, Research, UK Business Forums, Taste, Smoking, Management, Tobacco, Wood drying

LONDON, Nov. 10, 2023 /PRNewswire/ -- Smoore International revealed its FEELM 2.0, the first-ever disposable vape to offer more than 1,000 puffs in 2mL.

Key Points: 
  • LONDON, Nov. 10, 2023 /PRNewswire/ -- Smoore International revealed its FEELM 2.0, the first-ever disposable vape to offer more than 1,000 puffs in 2mL.
  • With the UK's 2mL e-liquid volume regulation limit, 600 puffs have been the industry benchmark for much of its time.
  • FEELM 2.0 is our disposable vape solution with the call sign 'Double the puff, double the joy.'
  • This is an area in which SMOORE is setting the pace with the launch of its newly developed FEELM 2.0."

The FEELM 2.0 Ushers in the New Generation of Disposable 2.0

Retrieved on: 
Friday, November 10, 2023
Pressure, Customer, Smoker, Research, Multimedia, UK Business Forums, Taste, Smoking, Management, Tobacco, Wood drying

LONDON, Nov. 10, 2023 /PRNewswire/ -- Smoore International revealed its FEELM 2.0, the first-ever disposable vape to offer more than 1,000 puffs in 2mL.

Key Points: 
  • LONDON, Nov. 10, 2023 /PRNewswire/ -- Smoore International revealed its FEELM 2.0, the first-ever disposable vape to offer more than 1,000 puffs in 2mL.
  • With the UK's 2mL e-liquid volume regulation limit, 600 puffs have been the industry benchmark for much of its time.
  • FEELM 2.0 is our disposable vape solution with the call sign 'Double the puff, double the joy.'
  • This is an area in which SMOORE is setting the pace with the launch of its newly developed FEELM 2.0."

Rothmans, Benson & Hedges Launches New Smoke-Free Heated Tobacco Product in Push to Lead Smoking Harm Reduction

Retrieved on: 
Thursday, November 9, 2023
Policy, Smoking, Benson, Smoke, Disease, PMI, Philip Morris International, Nicotine, Heated tobacco product, RBH, Science, N.B, Rothmans, Smoker, Tobacco, Burn

RBH's new heated tobacco product is the latest expansion of the company's growing portfolio of smoke-free innovations.

Key Points: 
  • RBH's new heated tobacco product is the latest expansion of the company's growing portfolio of smoke-free innovations.
  • The new bladeless SMARTCORE INDUCTION SYSTEM™ provides improved experience and is now available in select stores across Canada with four tobacco flavour options.
  • Cigarettes burn tobacco and create smoke, which contains high levels of harmful or potentially harmful chemicals – the primary cause of smoking related disease.
  • Under the federal Tobacco and Vaping Products Act, naming a heated tobacco product could be considered promotion.

22nd Century Group Continues VLN® Expansion, Now Retailing in More Than 5,100 Stores

Retrieved on: 
Wednesday, November 8, 2023
FDA, Health, XXII, Smoking, Century, Pacific Century Group, Disease, Smoker, Nicotine, Tobacco

With these latest additions, 22nd Century Group’s FDA-authorized VLN® reduced nicotine content cigarettes can now be found at more than 5,100 store locations spanning 23 states, including the addition of Washington, Oregon, Kentucky, and Louisiana.

Key Points: 
  • With these latest additions, 22nd Century Group’s FDA-authorized VLN® reduced nicotine content cigarettes can now be found at more than 5,100 store locations spanning 23 states, including the addition of Washington, Oregon, Kentucky, and Louisiana.
  • “The addition of over 500 new VLN® sales locations has propelled us beyond the noteworthy milestone of 5,100 stores.
  • We are pleased that an increasing number of adult smokers now have access to this important product if they are seeking new ways to reduce their smoking habit,” said Miller.
  • VLN® is the first and only FDA authorized combustible cigarette labelled as a tobacco harm reduction product.

Governments Need to Keep up with Innovative Breakthroughs to Benefit Public Health, Reveals International Survey Commissioned by PMI

Retrieved on: 
Wednesday, November 8, 2023
Other Consumer, FDA, Tobacco, Public Policy, Government, Health, Consumer, General Health, Retail, Smoke, Sale, Philip Morris International, Policy, Ageing, NYSE, Food, Life, Toxicology, Sportsheets International, Inc., Regulation of tobacco by the U.S. Food and Drug Administration, Research, Smoking, PMI, IQOS, Public, Smoker, Nicotine, ZYN

Over half of respondents (56 percent) believe their governments need to consider the role that smoke-free alternatives can play in eradicating cigarette use in their country.

Key Points: 
  • Over half of respondents (56 percent) believe their governments need to consider the role that smoke-free alternatives can play in eradicating cigarette use in their country.
  • “In the case of cigarettes, those paying the highest price are adult smokers in need of better options.
  • The survey reveals that citizens want their governments to embrace innovation and rely on scientific facts and data to guide their decision-making.
  • “Across the world, people are counting on their governments to stay on top of technological developments while ensuring innovative products are appropriately regulated,” said Verdeaux.

22nd Century Group (XXII) Expands Reduced Nicotine Content Tobacco IP with Latest Technology License

Retrieved on: 
Tuesday, November 7, 2023
FDA, Patent, Health, Smoke, Smoking, GMO, Century, Pacific Century Group, North Carolina State University, Public, Smoker, Nicotine, IP, Heated tobacco product, MRTP, Tobacco

BUFFALO, N.Y., Nov. 07, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII ), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hemp/cannabis, and hops, today announced the signing of an additional reduced nicotine content technology license with North Carolina State University.

Key Points: 
  • BUFFALO, N.Y., Nov. 07, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII ), a leading biotechnology company focused on utilizing advanced plant technologies to improve health and wellness with reduced nicotine tobacco, hemp/cannabis, and hops, today announced the signing of an additional reduced nicotine content technology license with North Carolina State University.
  • The latest license provides additional modes of efficiently producing reduced nicotine content tobacco plants, extending 22nd Century’s already extensive IP portfolio.
  • The license will provide 22nd Century Group exclusive rights to the technology until 2042.
  • “This latest license further enhances and expands on our capabilities to produce reduced nicotine content tobacco plants as we work to bring these innovative products to market for the betterment of public health, including by enhancing our capability to produce reduced nicotine content tobacco plants suitable for international markets that are opposed to genetically modified plants.”
    Under terms of the exclusive license, 22nd Century will have full use of the patent rights and plant materials to develop and commercialize reduced nicotine content tobacco using this latest non-GMO technology, which further enables worldwide marketability of the Company’s VLN® reduced nicotine content products.

Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally

Retrieved on: 
Tuesday, November 7, 2023
Biotechnology, Medical Devices, Health, Pharmaceutical, Oncology, Laboratory, Real-time, IVD, Physician, Illumina, Inc., CLIA, NGS, Cancer, Hospital, Smoker, Patient, Diagnosis, Pharmaceutical industry, Medical imaging, Illumina

(Nasdaq: VCYT) today announced that it has entered into a multi-year agreement with Illumina, Inc. (Nasdaq: ILMN) to develop and offer some of its high-performing molecular tests as decentralized in vitro diagnostic (IVD) tests on Illumina’s NextSeq 550Dx next-generation sequencing (NGS) instrument.

Key Points: 
  • (Nasdaq: VCYT) today announced that it has entered into a multi-year agreement with Illumina, Inc. (Nasdaq: ILMN) to develop and offer some of its high-performing molecular tests as decentralized in vitro diagnostic (IVD) tests on Illumina’s NextSeq 550Dx next-generation sequencing (NGS) instrument.
  • The agreement is part of Veracyte’s expanded, multi-platform IVD approach, which will also include qPCR and is designed to accelerate the company’s ability to make its tests available to more patients globally.
  • The first tests that Veracyte plans to develop for the Illumina NextSeq 550Dx instrument are its Prosigna Breast Cancer Assay and Percepta Nasal Swab test.
  • Prosigna is already commercially available as an IVD test that helps inform treatment decisions for patients with early-stage breast cancer.